Excerpts

Association Between EBV Status and PD-L1 Expression in Gastric Cancer Patients with EBV-positive gastric cancer showed a trend toward increased PD-L1 expression (CPS ≥ 1 and CPS ≥ 5) across all subgroups.

Discussion In this real-world study of patients with transplant-ineligible NDMM in Japan, those who received 1L DRd showed a trend toward an improvement in OS from the time of MM diagnosis by approximately 34% compared with 2L DRd (inverse HR of 0.658; 95% CI: 0.278, 1.563).

However, the p -value (0.0977) is marginally significant, suggesting that this result should be interpreted with caution.

The AUC value of its testing set was lower compared to that of O-RADS, but the difference was not significantly significant [ 47 ].

When compared to intravenous (IV) amivantamab, SC treatment demonstrated similar pharmacokinetics and a noninferior ORR (30.1%), with a positive trend in PFS (6.1 vs. 4.3 months), a longer median DOR (11.2 vs. 8.3 months for IV) and a better OS (HR 0.62 [0.42–0.92]).

More recently, a 2022 literature review showed a trend towards improved psychological outcomes following psychological prehabilitation, particularly when psychologist-led [ 65 ].

Additionally, the evaluation of gene expression may be significant in predicting responses to traditional anticancer treatments and determining patient prognosis.

Accordingly, we noted a nonsignificant trend towards RT compared to ADT in the salvage pN+ cohort.

For example, the increased Humbug expression in CDS11 cells may be significant in relation to its Ca2+ binding effects in the ER [ 85 ].

The data extracted from 91 peer-reviewed articles reveal a clear trend: IHC has become indispensable in the accurate identification and subclassification of SCC, particularly in cases with ambiguous histology or poorly differentiated features. 4.1.

Charlson–Deyo comorbidity score groups of one (HR 1.23, 95% CI 1.07–1.41), two (HR 2.36, 95% CI 1.93–2.88) and three or more (HR 3.72, 95% CI 3.11–4.45) were associated with worse OS rates compared to the score 0 group, demonstrating a clear trend of decreasing survival as the comorbidity burden increased.

In the CheckMate 238 trial, the efficacy of nivolumab was statistically significant for patients < 65 years (HR = 0.72, 95% CI 0.58–0.89), while in the older group of patients (25.8% of all included patients with age ≥ 65 years), the efficacy was not clearly significant (HR = 0.72, 95% CI 0.51–1.00).

This corresponded to reduced lymphatic density ( Figure 9 C) and a highly significant decrease of 85.8% in node metastatic burden ( Figure 9 D).

The duration of perioperative chemotherapy showed a trend toward improved survival outcomes, though not statistically significant (6 months vs. <6 months: DFS, 19.4 vs. 16.2 months, p = 0.1448; OS, 49.6 vs. 30.4 months, p = 0.0623).

Prognostic Factors for Overall Survival In the univariate Cox model for 5-year overall survival ( Table 5 ), the Sarculator OS score (HR 0.97, 95% CI 0.95–0.99, p < 0.001) and P-POSSUM mortality score (HR 1.15, 95% CI 1.08–1.23, p < 0.001) were significant predictors, while complications (HR 2.53, p = 0.08) showed a trend toward significance.

Overall survival in the entire cohort showed a trend favoring patients with tumor fibrosis > 40% (median survival = 51 months, 95% CI: 20.90–81.09) compared to those with fibrosis < 40% (median survival = 30 months, 95% CI: 22.83–37.16); log-rank test p = 0.036.

Primary tumor location did not reach statistical significance in the multivariate model (OR = 4.607 for left-sided tumors, 95% CI: 0.854–24.855; p = 0.076), but it was retained due to potential clinical relevance, small sample size, and a p -value approaching significance.

Patients with intermediate BAG3 scores (score 1 and score 2) had mean disease-free survival times of 23.8 and 23.2 months, respectively—both shorter than BAG3-negative patients—implying a possible trend which needs further investigation. 4.

A nearly significant value was reported comparing the median duration of HHI treatment between locally advanced BCC patients who experienced tumor relapse (15 months [range: 7–20 months]) versus locally advanced BCC patients who did not recur (18 months [range: 1–37 months], p : 0.06).

Although its association with disease-free recurrence did not reach significance, a clear trend was observed.

Most MSI cases (91%, Table 1 ) had endometrioid histology, were early-stage I–II (86.4%, Table 1 , Figure 1 B), and showed a trend toward a high grade, significantly greater than the NSMP group (grade MSI vs.

Consistent with this, telomere length values were also observed to be higher in AML, and the telomere length values followed a decreasing trend first in T-cell ALL and then in B-cell ALL, confirming the reversing action of telomerase against telomere shortening [ 186 ].

It is also worth noting that the analysis of changes in the values of hemorheological parameters, such as aggregability of erythrocytes and plasma viscosity, may be significant because thromboembolic events may be the cause of complications in the process of surgical and chemotherapeutic treatments of cancer.

CRC Screening and Health Policy—Bottom Line CRC screening rates have undoubtedly increased over the past decades and were on an increasing trend in the pre-ACA era; from 2000 to 2019, a linear increase in CRC screening prevalence among individuals aged 50–75 can be seen from CDC data.

Results : The EA group demonstrated a clear trend toward improved local recurrence-free survival (LRFS, EA median 35 months vs.